Appendix 1 – Results of all years MTC adjusted for baseline ARR

Results of all years MTC adjusted for baseline ARR

Table A.1.1 Annualised relapse rates RR (all years adjusted for baseline ARR)

	Alemtuzumab 12mg	Placebo
	Rate Ratio [95% CrI]	
Alemtuzumab 12mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]

Table A.1.2 SAD 3 month HR (all years adjusted for baseline ARR)

	Alemtuzumab 12mg	Placebo
	Hazard Ratio [95% CrI]	
Alemtuzumab 12mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 22 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]

Table A.1.3. Discontinuation rate ORs (all years MTC adjusted for baseline ARR)

	Teriflunomide 14mg
Teriflunomide 14mg	
IFNβ-1b 250 µg	[redacted]
IM IFNβ-1a 30 µg	[redacted]
SC IFNβ-1a 22 µg	[redacted]
SC IFNβ-1a 44 µg	[redacted]
GA 20 mg	[redacted]

Table A.1.4. SAD 6 month HR (all years adjusted for baseline ARR)

	Alemtuzumab 12mg	Placebo
	Hazard Ratio [95% CrI]	
Alemtuzumab 12mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]